A Phase 1, Double Blind Study Of The Safety And Pharmacokinetics Of Multiple Doses Of CE 224,535 In Subjects With Rheumatoid Arthritis Receiving Methotrexate.
Phase of Trial: Phase I
Latest Information Update: 20 May 2011
At a glance
- Drugs CE 224535 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Pfizer
- 20 May 2011 Actual end date (Aug 2007) added as reported by ClinicalTrials.gov.
- 22 Oct 2007 Status changed from recruiting to completed.
- 02 May 2007 New trial record.